ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Jun 12, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, 6-K, regulatory-update
TL;DR
IPA files 6-K with press release on June 12, 2024. Stay tuned for updates.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 12, 2024, to report information as a foreign private issuer. The filing includes a press release dated June 12, 2024, as Exhibit 99.1. The company's principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing provides updated information to the SEC, which is crucial for investors to stay informed about the company's ongoing activities and disclosures.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would inherently increase risk.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Chief Financial Officer
- June 12, 2024 (date) — Filing and Press Release Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC.
What is included as an exhibit in this filing?
Exhibit 99.1 is a Press Release dated June 12, 2024.
Who signed this report on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor, Chief Financial Officer, signed the report on June 12, 2024.
Where are ImmunoPrecise Antibodies Ltd.'s principal executive offices located?
The principal executive offices are located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Is ImmunoPrecise Antibodies Ltd. required to file annual reports under Form 20-F or Form 40-F?
The filing indicates that the registrant files or will file annual reports under Form 20-F.
Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-06-12 13:01:33
Filing Documents
- form6k.htm (6-K) — 4KB
- exhibit99-1.htm (EX-99.1) — 8KB
- 0001062993-24-012451.txt ( ) — 13KB
From the Filing
ImmunoPrecise Antibodies Ltd.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 . Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: June 12, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer EXHIBIT INDEX 99.1 Press Release dated June 12, 2024